TRENDS

Foreign Drug Makers Seeking to Offset Risk in US, European Markets by Driving Growth in “Attractive” Japanese Market

May 23, 2014
Drug makers have announced their FY2013 settlements of accounts. According to IMS Japan, the domestic drug market grew just 3.1% from January through December 2013 despite the lack of an NHI price revision, poor growth compared to 2011 (+6.9%) and…

To read the full story

TRENDS

By Reiji Anasako

Drug makers’ sales forces have continued to shrink over the last few years. As the shift from primary fields to specialty arenas and the loss of patent protection for major products have transformed drug makers’ product mix, fewer sales reps…

By Philip Carrigan

If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…